Resistin Impairs Insulin-Evoked Vasodilation

Resistin Impairs Insulin-Evoked Vasodilation Maria Teresa Gentile 1 , Carmine Vecchione 1 , Gennaro Marino 1 , Alessandra Aretini 1 , Alba Di Pardo 1 , Giovanna Antenucci 1 , Angelo Maffei 1 , Giuseppe Cifelli 1 , Luca Iorio 1 , Alessandro Landolfi 1 , Giacomo Frati 2 and Giuseppe Lembo 1 , 2 1 Depa...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 57; no. 3; pp. 577 - 583
Main Authors Gentile, Maria Teresa, Vecchione, Carmine, Marino, Gennaro, Aretini, Alessandra, Di Pardo, Alba, Antenucci, Giovanna, Maffei, Angelo, Cifelli, Giuseppe, Iorio, Luca, Landolfi, Alessandro, Frati, Giacomo, Lembo, Giuseppe
Format Journal Article
LanguageEnglish
Published Alexandria, VA American Diabetes Association 01.03.2008
Subjects
Online AccessGet full text
ISSN0012-1797
1939-327X
1939-327X
DOI10.2337/db07-0557

Cover

Loading…
Abstract Resistin Impairs Insulin-Evoked Vasodilation Maria Teresa Gentile 1 , Carmine Vecchione 1 , Gennaro Marino 1 , Alessandra Aretini 1 , Alba Di Pardo 1 , Giovanna Antenucci 1 , Angelo Maffei 1 , Giuseppe Cifelli 1 , Luca Iorio 1 , Alessandro Landolfi 1 , Giacomo Frati 2 and Giuseppe Lembo 1 , 2 1 Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy 2 Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Rome, Italy Address correspondence and reprint requests to Giuseppe Lembo, MD, PhD, La Sapienza University of Rome, c/o Neuromed Institute, Località Camerelle, 86077 Pozzilli (IS), Italy. E-mail: lembo{at}neuromed.it Abstract OBJECTIVE —Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity. RESEARCH DESIGN AND METHODS —We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting. RESULTS —Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase. CONCLUSIONS —Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation. eNOS, endothelial nitric oxide synthase IRS, insulin receptor substrate l -NAME, l - N G -nitro- l -arginine methyl ester PI, phosphatidylinositol Footnotes Published ahead of print at http://diabetes.diabetesjournals.org on 7 December 2007. DOI: 10.2337/db07-0557. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received April 24, 2007. Accepted November 27, 2007. DIABETES
AbstractList Resistin Impairs Insulin-Evoked Vasodilation Maria Teresa Gentile 1 , Carmine Vecchione 1 , Gennaro Marino 1 , Alessandra Aretini 1 , Alba Di Pardo 1 , Giovanna Antenucci 1 , Angelo Maffei 1 , Giuseppe Cifelli 1 , Luca Iorio 1 , Alessandro Landolfi 1 , Giacomo Frati 2 and Giuseppe Lembo 1 , 2 1 Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy 2 Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Rome, Italy Address correspondence and reprint requests to Giuseppe Lembo, MD, PhD, La Sapienza University of Rome, c/o Neuromed Institute, Località Camerelle, 86077 Pozzilli (IS), Italy. E-mail: lembo{at}neuromed.it Abstract OBJECTIVE —Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity. RESEARCH DESIGN AND METHODS —We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting. RESULTS —Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase. CONCLUSIONS —Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation. eNOS, endothelial nitric oxide synthase IRS, insulin receptor substrate l -NAME, l - N G -nitro- l -arginine methyl ester PI, phosphatidylinositol Footnotes Published ahead of print at http://diabetes.diabetesjournals.org on 7 December 2007. DOI: 10.2337/db07-0557. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received April 24, 2007. Accepted November 27, 2007. DIABETES
OBJECTIVE—Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity. RESEARCH DESIGN AND METHODS—We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting. RESULTS—Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase. CONCLUSIONS—Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation.
Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity. We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting. Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase. Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation.
Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity. We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting. Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase. Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation.
Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity.OBJECTIVESince vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity.We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting.RESEARCH DESIGN AND METHODSWe performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting.Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase.RESULTSRecombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase.Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation.CONCLUSIONSOur results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation.
Audience Professional
Author Luca Iorio
Angelo Maffei
Maria Teresa Gentile
Alessandro Landolfi
Alba Di Pardo
Giuseppe Cifelli
Gennaro Marino
Giovanna Antenucci
Giacomo Frati
Giuseppe Lembo
Carmine Vecchione
Alessandra Aretini
Author_xml – sequence: 1
  givenname: Maria Teresa
  surname: Gentile
  fullname: Gentile, Maria Teresa
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 2
  givenname: Carmine
  surname: Vecchione
  fullname: Vecchione, Carmine
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 3
  givenname: Gennaro
  surname: Marino
  fullname: Marino, Gennaro
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 4
  givenname: Alessandra
  surname: Aretini
  fullname: Aretini, Alessandra
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 5
  givenname: Alba
  surname: Di Pardo
  fullname: Di Pardo, Alba
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 6
  givenname: Giovanna
  surname: Antenucci
  fullname: Antenucci, Giovanna
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 7
  givenname: Angelo
  surname: Maffei
  fullname: Maffei, Angelo
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 8
  givenname: Giuseppe
  surname: Cifelli
  fullname: Cifelli, Giuseppe
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 9
  givenname: Luca
  surname: Iorio
  fullname: Iorio, Luca
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 10
  givenname: Alessandro
  surname: Landolfi
  fullname: Landolfi, Alessandro
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
– sequence: 11
  givenname: Giacomo
  surname: Frati
  fullname: Frati, Giacomo
  organization: Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Rome, Italy
– sequence: 12
  givenname: Giuseppe
  surname: Lembo
  fullname: Lembo, Giuseppe
  organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy, Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Rome, Italy
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20181688$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18065520$$D View this record in MEDLINE/PubMed
BookMark eNpt0l9rUzEUAPAgE9dVH_wCUgQHinfLnya593GUOQuFgaj4FtLk3LvMNKnJvTq_vamtlo4SSEL4nUNycs7QSYgBEHpJ8AVlTF7aJZYV5lw-QSPSsKZiVH47QSOMCa2IbOQpOsv5HmMsyniGTkmNBecUj9D7T5Bd7l2YzFdr7VKezEMevAvV9c_4Hezkq87ROq97F8Nz9LTVPsOL3TpGXz5cf559rBa3N_PZ1aIygvK-0gCYMzw1FqQmmPCGWKbbli2FJqbmTBANwmLGqRQWpnXdCgq8GCrBNpKN0fk27zrFHwPkXq1cNuC9DhCHrCRmU8YlK_D1I3gfhxTK3RQlYloLWuAYVVvUaQ_KhTb2SZsOAiTtSyFbV46viBSCU9HQ4i-O-DIsrJw5GvD2IKCYHh76Tg85q_pmcWirY9ZE76EDVco4uz30r3YvHJYrsGqd3Eqn3-rfDxbwZgd0Ntq3SQfj8n9HMamJqOv9JU2KOSdo96mw2nSR2nSR2nRRsZePrHH93w4olXD-aMS7bcSd6-5-uQTKOr2EHvJ-w6ViZZLsD1uS0kQ
CODEN DIAEAZ
CitedBy_id crossref_primary_10_1016_j_cardfail_2010_05_027
crossref_primary_10_1155_2017_2712751
crossref_primary_10_1007_s12020_015_0709_4
crossref_primary_10_1038_srep22193
crossref_primary_10_1249_MSS_0b013e3181ba6dd3
crossref_primary_10_1016_j_bbrc_2009_04_074
crossref_primary_10_1111_j_1748_1716_2008_01891_x
crossref_primary_10_1113_JP282728
crossref_primary_10_1016_j_clinbiochem_2013_10_021
crossref_primary_10_1007_s00421_024_05468_5
crossref_primary_10_3177_jnsv_60_52
crossref_primary_10_1074_jbc_RA118_004882
crossref_primary_10_1111_andr_12853
crossref_primary_10_1002_cbin_10595
crossref_primary_10_1016_j_bcp_2024_116245
crossref_primary_10_1111_bph_12993
crossref_primary_10_1016_j_atherosclerosis_2014_07_027
crossref_primary_10_1152_physrev_00034_2018
crossref_primary_10_1248_bpb_34_307
crossref_primary_10_1111_bph_13767
crossref_primary_10_1038_jhh_2010_22
crossref_primary_10_1155_2013_230868
crossref_primary_10_3389_fphar_2018_01226
crossref_primary_10_1007_s11906_012_0259_6
crossref_primary_10_1080_07315724_2014_933685
crossref_primary_10_1254_fpj_137_131
crossref_primary_10_1016_j_regpep_2008_07_008
crossref_primary_10_18821_0023_2149_2017_95_4_322_327
crossref_primary_10_1016_j_mam_2019_02_003
crossref_primary_10_1111_j_1476_5381_2011_01369_x
crossref_primary_10_1371_journal_pone_0089745
crossref_primary_10_1016_j_bbrc_2010_02_053
crossref_primary_10_1152_ajpendo_00578_2012
crossref_primary_10_1152_ajpheart_00431_2009
crossref_primary_10_3233_JAD_181079
crossref_primary_10_1186_s12876_017_0592_y
crossref_primary_10_3390_cells12081196
crossref_primary_10_1002_dmrr_907
crossref_primary_10_3389_fmed_2022_844266
crossref_primary_10_1038_hr_2008_35
crossref_primary_10_14341_omet201745_9
crossref_primary_10_1139_y2012_053
crossref_primary_10_1186_1741_7015_9_25
crossref_primary_10_1007_s00125_013_3016_8
crossref_primary_10_1007_s00441_015_2274_9
Cites_doi 10.1016/S0092-8674(01)00239-2
10.1038/oby.2003.137
10.1161/01.HYP.0000082806.73530.68
10.1074/jbc.M211926200
10.1161/01.CIR.0000147825.97879.E7
10.1074/jbc.M407358200
10.1007/s00125-003-1228-z
10.1210/jc.2003-030519
10.1074/jbc.M101521200
10.1152/ajpendo.1994.267.2.E187
10.1016/j.atherosclerosis.2006.05.039
10.1152/physrev.1995.75.3.473
10.1016/S0021-9258(17)37568-3
10.1038/21218
10.1016/S0002-9149(03)00611-8
10.1146/annurev.bi.63.070194.001135
10.1111/j.1365-2265.2005.02207.x
10.1038/oby.2002.1
10.1172/JCI200421270
10.1177/153537020523000901
10.1161/01.RES.43.6.854
10.2337/diabetes.52.8.1943
10.1056/NEJM198708063170605
10.1016/S0008-6363(99)00094-2
10.1038/21224
10.2337/diabetes.50.1.159
10.1210/endo.142.7.8283
10.1016/S1043-2760(98)00110-6
10.1210/jc.2005-1653
10.2337/diabetes.48.7.1359
10.1016/j.tcm.2006.03.008
10.1172/JCI10582
10.1111/j.1365-2265.2007.02743.x
10.1161/01.CIR.0000084503.91330.49
10.1172/JCI16521
10.1172/JCI118871
10.1161/01.STR.0000038989.90931.BE
10.2337/diacare.14.3.173
10.1038/414799a
10.1172/JCI20785
10.1111/j.1365-2796.2004.01306.x
10.1046/j.1464-5491.1999.00023.x
10.1530/eje.0.1490331
10.1007/s00125-005-0060-z
10.1038/35053000
10.1074/jbc.M103702200
ContentType Journal Article
Copyright 2008 INIST-CNRS
COPYRIGHT 2008 American Diabetes Association
COPYRIGHT 2008 American Diabetes Association
Copyright American Diabetes Association Mar 2008
Copyright_xml – notice: 2008 INIST-CNRS
– notice: COPYRIGHT 2008 American Diabetes Association
– notice: COPYRIGHT 2008 American Diabetes Association
– notice: Copyright American Diabetes Association Mar 2008
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
8GL
3V.
7RV
7X7
7XB
88E
88I
8AF
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
K9-
K9.
KB0
LK8
M0R
M0S
M1P
M2O
M2P
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
S0X
7X8
DOI 10.2337/db07-0557
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: High School
ProQuest Central (Corporate)
Proquest Nursing & Allied Health Source
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
eLibrary Curriculum
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
ProQuest Research Library
Science Database
Biological Science Database
Research Library (Corporate)
ProQuest Nursing and Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
SIRS Editorial
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
elibrary
ProQuest AP Science
SciTech Premium Collection
ProQuest Central China
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
SIRS Editorial
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Research Library
ProQuest Public Health
ProQuest Central Basic
ProQuest Science Journals
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
Research Library Prep
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1939-327X
EndPage 583
ExternalDocumentID 1453078811
A176652692
18065520
20181688
10_2337_db07_0557
diabetes_57_3_577
Genre Journal Article
GroupedDBID -
08R
0R
1AW
29F
2WC
3V.
4.4
53G
55
5GY
5RE
5RS
5VS
7RV
7X7
88E
88I
8AF
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8GL
8R4
8R5
AAQQT
AAWTL
AAYEP
AAYJJ
ABFLS
ABOCM
ABPTK
ABUWG
ACDCL
ACGOD
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AFKRA
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BAWUL
BBAFP
BBNVY
BCR
BCU
BEC
BENPR
BES
BHPHI
BKEYQ
BKNYI
BLC
BPHCQ
BVXVI
C1A
CS3
DIK
DU5
DWQXO
E3Z
EBS
EDB
EJD
EX3
F5P
FRP
FYUFA
GICCO
GJ
GNUQQ
GUQSH
GX1
H13
HCIFZ
HZ
H~9
IAG
IAO
IEA
IHR
INH
INR
IOF
IPO
K-O
K9-
KM
KQ8
L7B
LK8
M0R
M1P
M2O
M2P
M2Q
M5
M7P
MBDVC
O0-
O5R
O5S
O9-
OB3
OBH
OK1
OVD
P2P
PADUT
PCD
PEA
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
Q2X
RHF
RHI
RPM
S0X
SJFOW
SJN
SV3
TDI
WH7
WOQ
WOW
X7M
XZ
ZA5
ZY1
---
.55
.GJ
.XZ
08P
0R~
18M
354
6PF
AAFWJ
AAKAS
AAYOK
AAYXX
ACGFO
ADGHP
ADZCM
AEGXH
AERZD
AIAGR
AIZAD
ALIPV
BTFSW
CCPQU
CITATION
EMOBN
HMCUK
HZ~
ITC
K2M
M5~
N4W
NAPCQ
OHH
PHGZM
PHGZT
TEORI
TR2
UKHRP
VVN
W8F
YFH
YHG
YOC
~KM
1CY
8F7
AFFNX
AI.
IQODW
J5H
MVM
PJZUB
PPXIY
PQGLB
VH1
XOL
YQJ
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FK
K9.
PKEHL
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-c625t-aee05304cde7a101591d3aff3b6a1c85361ae6d035276de488f62e5d3a27ed973
IEDL.DBID BENPR
ISSN 0012-1797
1939-327X
IngestDate Sun Aug 24 03:43:23 EDT 2025
Fri Jul 25 19:27:40 EDT 2025
Fri Jun 13 00:42:06 EDT 2025
Tue Jun 10 21:31:03 EDT 2025
Fri Jun 27 03:48:20 EDT 2025
Tue Jun 10 19:35:34 EDT 2025
Mon Jul 21 05:45:31 EDT 2025
Mon Jul 21 09:17:54 EDT 2025
Tue Jul 01 03:03:58 EDT 2025
Thu Apr 24 22:51:46 EDT 2025
Fri Jan 15 19:45:56 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Endocrinopathy
Pancreatic hormone
Vasomotricity
Diabetes mellitus
Insulin
Vasodilation
Resistin
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c625t-aee05304cde7a101591d3aff3b6a1c85361ae6d035276de488f62e5d3a27ed973
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://diabetesjournals.org/diabetes/article-pdf/57/3/577/389966/zdb00308000577.pdf
PMID 18065520
PQID 216486234
PQPubID 34443
PageCount 7
ParticipantIDs gale_incontextcollege_GICCO_A176652692
highwire_diabetes_diabetes_57_3_577
gale_infotracgeneralonefile_A176652692
pascalfrancis_primary_20181688
crossref_primary_10_2337_db07_0557
pubmed_primary_18065520
proquest_journals_216486234
gale_incontextgauss_8GL_A176652692
crossref_citationtrail_10_2337_db07_0557
gale_infotracacademiconefile_A176652692
proquest_miscellaneous_70343573
ProviderPackageCode RHF
RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2008-03-01
PublicationDateYYYYMMDD 2008-03-01
PublicationDate_xml – month: 03
  year: 2008
  text: 2008-03-01
  day: 01
PublicationDecade 2000
PublicationPlace Alexandria, VA
PublicationPlace_xml – name: Alexandria, VA
– name: United States
– name: New York
PublicationTitle Diabetes (New York, N.Y.)
PublicationTitleAlternate Diabetes
PublicationYear 2008
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
References 2022031304032683900_R40
2022031304032683900_R11
2022031304032683900_R33
2022031304032683900_R10
2022031304032683900_R32
2022031304032683900_R31
2022031304032683900_R30
2022031304032683900_R15
2022031304032683900_R37
2022031304032683900_R14
2022031304032683900_R36
2022031304032683900_R13
2022031304032683900_R35
2022031304032683900_R12
2022031304032683900_R34
2022031304032683900_R19
2022031304032683900_R18
2022031304032683900_R17
2022031304032683900_R39
2022031304032683900_R16
2022031304032683900_R38
2022031304032683900_R6
2022031304032683900_R5
2022031304032683900_R4
2022031304032683900_R3
2022031304032683900_R9
2022031304032683900_R8
2022031304032683900_R7
2022031304032683900_R22
2022031304032683900_R44
2022031304032683900_R21
2022031304032683900_R43
2022031304032683900_R20
2022031304032683900_R42
2022031304032683900_R41
2022031304032683900_R2
2022031304032683900_R26
2022031304032683900_R48
2022031304032683900_R1
2022031304032683900_R25
2022031304032683900_R47
2022031304032683900_R24
2022031304032683900_R46
2022031304032683900_R23
2022031304032683900_R45
2022031304032683900_R29
2022031304032683900_R28
2022031304032683900_R27
Diabetes. 2010 Jan;59(1):319
References_xml – ident: 2022031304032683900_R3
  doi: 10.1016/S0092-8674(01)00239-2
– ident: 2022031304032683900_R21
  doi: 10.1038/oby.2003.137
– ident: 2022031304032683900_R6
  doi: 10.1161/01.HYP.0000082806.73530.68
– ident: 2022031304032683900_R37
  doi: 10.1074/jbc.M211926200
– ident: 2022031304032683900_R32
  doi: 10.1161/01.CIR.0000147825.97879.E7
– ident: 2022031304032683900_R14
  doi: 10.1074/jbc.M407358200
– ident: 2022031304032683900_R8
  doi: 10.1007/s00125-003-1228-z
– ident: 2022031304032683900_R13
– ident: 2022031304032683900_R26
  doi: 10.1210/jc.2003-030519
– ident: 2022031304032683900_R45
  doi: 10.1074/jbc.M101521200
– ident: 2022031304032683900_R5
  doi: 10.1152/ajpendo.1994.267.2.E187
– ident: 2022031304032683900_R31
  doi: 10.1016/j.atherosclerosis.2006.05.039
– ident: 2022031304032683900_R1
  doi: 10.1152/physrev.1995.75.3.473
– ident: 2022031304032683900_R44
  doi: 10.1016/S0021-9258(17)37568-3
– ident: 2022031304032683900_R17
  doi: 10.1038/21218
– ident: 2022031304032683900_R48
  doi: 10.1016/S0002-9149(03)00611-8
– ident: 2022031304032683900_R35
  doi: 10.1146/annurev.bi.63.070194.001135
– ident: 2022031304032683900_R29
  doi: 10.1111/j.1365-2265.2005.02207.x
– ident: 2022031304032683900_R16
  doi: 10.1038/oby.2002.1
– ident: 2022031304032683900_R24
  doi: 10.1172/JCI200421270
– ident: 2022031304032683900_R40
  doi: 10.1177/153537020523000901
– ident: 2022031304032683900_R27
– ident: 2022031304032683900_R15
  doi: 10.1161/01.RES.43.6.854
– ident: 2022031304032683900_R47
  doi: 10.2337/diabetes.52.8.1943
– ident: 2022031304032683900_R4
  doi: 10.1056/NEJM198708063170605
– ident: 2022031304032683900_R36
  doi: 10.1016/S0008-6363(99)00094-2
– ident: 2022031304032683900_R18
  doi: 10.1038/21224
– ident: 2022031304032683900_R19
  doi: 10.2337/diabetes.50.1.159
– ident: 2022031304032683900_R43
  doi: 10.1210/endo.142.7.8283
– ident: 2022031304032683900_R10
  doi: 10.1016/S1043-2760(98)00110-6
– ident: 2022031304032683900_R30
  doi: 10.1210/jc.2005-1653
– ident: 2022031304032683900_R41
  doi: 10.2337/diabetes.48.7.1359
– ident: 2022031304032683900_R42
  doi: 10.1016/j.tcm.2006.03.008
– ident: 2022031304032683900_R39
  doi: 10.1172/JCI10582
– ident: 2022031304032683900_R28
  doi: 10.1111/j.1365-2265.2007.02743.x
– ident: 2022031304032683900_R7
  doi: 10.1161/01.CIR.0000084503.91330.49
– ident: 2022031304032683900_R12
  doi: 10.1172/JCI16521
– ident: 2022031304032683900_R33
  doi: 10.1172/JCI118871
– ident: 2022031304032683900_R20
  doi: 10.1161/01.STR.0000038989.90931.BE
– ident: 2022031304032683900_R2
  doi: 10.2337/diacare.14.3.173
– ident: 2022031304032683900_R46
  doi: 10.1038/414799a
– ident: 2022031304032683900_R25
  doi: 10.1172/JCI20785
– ident: 2022031304032683900_R23
  doi: 10.1111/j.1365-2796.2004.01306.x
– ident: 2022031304032683900_R9
  doi: 10.1046/j.1464-5491.1999.00023.x
– ident: 2022031304032683900_R22
  doi: 10.1530/eje.0.1490331
– ident: 2022031304032683900_R38
  doi: 10.1007/s00125-005-0060-z
– ident: 2022031304032683900_R11
  doi: 10.1038/35053000
– ident: 2022031304032683900_R34
  doi: 10.1074/jbc.M103702200
– reference: - Diabetes. 2010 Jan;59(1):319
SSID ssj0006060
Score 2.1557245
Snippet Resistin Impairs Insulin-Evoked Vasodilation Maria Teresa Gentile 1 , Carmine Vecchione 1 , Gennaro Marino 1 , Alessandra Aretini 1 , Alba Di Pardo 1 ,...
OBJECTIVE—Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently...
Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone...
SourceID proquest
gale
pubmed
pascalfrancis
crossref
highwire
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 577
SubjectTerms Adaptor Proteins, Signal Transducing - metabolism
Adipocytes
Aging
Animals
Aorta - drug effects
Aorta - metabolism
Biological and medical sciences
Blood pressure
Body fat
Care and treatment
Cells, Cultured
Diabetes
Diabetes mellitus
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Endothelial Cells - drug effects
Endothelial Cells - metabolism
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Glucose
Health aspects
Hormones
Insulin - blood
Insulin - metabolism
Insulin - pharmacology
Insulin Receptor Substrate Proteins
Insulin resistance
Kinases
Male
Medical sciences
Mesenteric Arteries - drug effects
Mesenteric Arteries - metabolism
Mice
Mice, Inbred C57BL
Musculoskeletal system
Nitric oxide
Nitric Oxide Synthase Type III - antagonists & inhibitors
Nitric Oxide Synthase Type III - metabolism
Obesity
Phosphatidylinositol 3-Kinases - metabolism
Phosphorylation
Plasma
Proto-Oncogene Proteins c-akt - metabolism
Research design
Resistin - blood
Resistin - metabolism
Resistin - pharmacology
Vasodilation - drug effects
Title Resistin Impairs Insulin-Evoked Vasodilation
URI http://diabetes.diabetesjournals.org/content/57/3/577.abstract
https://www.ncbi.nlm.nih.gov/pubmed/18065520
https://www.proquest.com/docview/216486234
https://www.proquest.com/docview/70343573
Volume 57
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED-NIk17mfa9wNZFbGJ7WES-HKdPiFVlMA02oTH1zXJsByFQArjd37-72glEYnuJIvXXNj77Puy7_A7gQ67Rrcq4jiptVJQXZR3JGO_SvMZJrlhSr0h9jo6Lg9P825zNfW2O9WWVnU1cGWrdKjoj30kxrsfoO8t3r64jahpFyVXfQWMN1tECl2wE619mxz9PelOM0bl7ByVJiYeTO2qhNMv4jq7ojI6RW7rjkDqz3HEFU6mktCit2rW5-HccuvJH-0_gsQ8kwz0380_hgWmewcMjnyp_Dp9PjCX9bcJD1PjzGxseurLzaPanvTA6_C1tq89dKdwLON2f_ZoeRL41QqRww7KIpKGWDnGutOEStYpNEp3Jus6qQiYKXXCRSFNoIjvlhTaopXWRGoaYlBs94dlLGDVtY15DSLvUmEtV4fdwb8hLSuhi3FJNWCmrJA3gUycfoTxvOLWvuBS4fyBRChKlIFEGsNVDrxxZxn2gbRKyIPKJhqpblDshETi-6Q-xR4yV1PYc_3hrCDyTS2tF-fX7APTRg-oWn0pJ_1YBjo2IrQbI7QHyzNF63wd8302_6A7Ab28YFxlecBjjwcroB5wSBVpRlgFsdktFeLtgRb-KA3jXf4oKTVka2Zh2aQWaYAxheRbAK7e-bkVJSXCWxhv__eVNeORqWqhO7g2MFjdL8xYDp0U1hjU-53gtp8nYq8pfCKsWVg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dT9RAEJ8gJOqL8dsKQoOKPNjQbj-292AM4OGd3J2GgOFt3XZ3CdG0QO80_lH-j87ctoUm6BsvlyY3_djZ2fnYmf0NwKtIoVmVvvEypXMvSlLjSR-vWGRwkrM4MHNQn_EkGRxFn47j4wX405yFobLKRifOFbUqc9oj32Lo16P3HUbvz849ahpFydWmg4aVin39-xdGbNW74Qec3teM7fUPdwde3VTAy9HVn3pSUzMEP8qV5hLlMe4FKpTGhFkigxyNVxJInSiCCeWJ0ijfJmE6RhrGterxEJ97C5bQy-jhIlra6U--HLSqH6MBe-YlYIT7yS2UEQtDvqUy2hOMyQxeMYCNGWiwiak0U1Y4O8a21fi33zu3f3v34V7tuLrbVtIewIIuHsLtcZ2afwRvD3RF-qJwh6hhTi8qd2jL3L3-z_K7Vu5XWZXq1JbePYajG-HaE1gsykI_A5eiYp_LPMP7MBblKSWQ0U_KenEqs4A5sNnwR-Q1Tjm1y_ghMF4hVgpipSBWOrDekp5ZcI7riDaIyYLALgqqpsntjozA8e1-FtuEkElt1vHF613CEzmrKpF-HHWI3tREpsSvymV9igHHRkBaHcqNDuWJhRG_jvBlM_2i2XC_vIi5CPEHh7HakYx2wIwg15I0dWC5ERVR66FKtKvGgbX2X1QglBWShS5nlUCVj8LMQweeWvm6ZCUl3WPmP__vk9fgzuBwPBKj4WR_Ge7aehqq0VuBxenFTL9Ap22ardZLxYVvN706_wKTl1Gp
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEB6VIlW8oHKbltYqUHjAir0-1nlAqEobGnqAEEV9W9Z7VFUru62TIn4a_46ZrJ1gqfDWl8hSxsfOzs6xM_sNwKtEo1mVoQ0KbVSQZLkNZIhXLLE4yUUa2Smoz8FhtnuUfDpOjxfgd3sWhsoqW504VdS6UrRH3mPo16P3HSc921RFfNkefri4DKiBFCVa224aTkL2zK-fGL3V70fbONWvGRvufBvsBk2DgUCh2z8OpKHGCGGitOESZTPtRzqW1sZFJiOFhiyLpMk0QYbyTBuUdZsxkyIN40b3eYzPvQN3ecxz6hqRD-bVJRgXuNMvESMEUO5AjVgc854uaHcwJYP4lylsDUKLUkxFmrLGebKuwca_PeCpJRwuw_3GhfW3nMw9gAVTPoSlgyZJ_wjefTU1aY7SH6GuOb2q_ZEreA92rqszo_3vsq70qSvCewxHt8KzJ7BYVqV5Bj7FxyGXqsD7MCrlOaWS0WMq-mkui4h58Lblj1ANYjk1zjgXGLkQKwWxUhArPdiYkV44mI6biDaJyYJgL0qSIOX2ZgSOb_BZbBFWJjVcxxdvdAlP5KSuRf5xv0P0piGyFX6Vks15BhwbQWp1KDc7lCcOUPwmwpft9It2631-kXIR4w8OY60jGbMBMwJfy_Lcg5VWVESjkWoxWz8erM_-RVVC-SFZmmpSC1T-6Dzz2IOnTr7mrKT0e8rC5_998jos4ZoU-6PDvRW45wprqFhvFRbHVxPzAr23cbE2XSc-_LjthfkHJqVUOw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Resistin+impairs+insulin-evoked+vasodilation&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=Gentile%2C+Maria+Teresa&rft.au=Vecchione%2C+Carmine&rft.au=Marino%2C+Gennaro&rft.au=Aretini%2C+Alessandra&rft.date=2008-03-01&rft.eissn=1939-327X&rft.volume=57&rft.issue=3&rft.spage=577&rft_id=info:doi/10.2337%2Fdb07-0557&rft_id=info%3Apmid%2F18065520&rft.externalDocID=18065520
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon